This technology assesses the role of irradiation therapy for cancer treatment and its impact on adenosine signaling.
Adenosine signaling is a immune response mediating pathway through which sustained signaling is implicated in promoting cancer progression via disruption of anti-tumor immunity. Adenosine signaling has been suggested to have prognostic value for cancer treatment and outcomes. However, current understanding of the underlying mechanisms in this pathway and their role in promoting tumor progression is limited. As adenosine signaling is a conserved signaling pathway, further study of its relationship with immune signaling and the tumor microenvironment may identify potential therapeutic targets across multiple cancers.
This technology assesses the impact of tumor irradiation on adenosine signaling and the tumor immune microenvironment. Pre-clinical data was collected and a preclinical pipeline was established to study the relationship between radiotherapy and the adenosine signaling pathway. Chemical compounds to therapeutically modulate and target the adenosine signaling pathway were identified. Similarly, this technology evaluates these chemical compounds in combination with radiotherapy. As such, this technology has therapeutic potential involving the use of radiotherapy, development of immunotherapies for cancers and autoimmune diseases, and further research on molecular mechanisms underlying the adenosine signaling pathway.
This technology has been validated with pre-clinical data and tumor models.
IR CU22323
Licensing Contact: Joan Martinez